Document is current
Any future updates will be listed below
-
Authors
Santisteban, Victoria
López-Yerena, Anallely
Muñoz-Garcia, Natàlia
Vilahur, Gemma
Badimon, Lina
Padro, Teresa https://orcid.org/0000-0003-1921-954X
-
Funding
Funding for this research was provided by:
Agencia Estatal de Investigación (PID2021-128891OB-I00, PID2019-107160RB-I00)
Instituto de Salud Carlos III (PI22/01930)
- License Information
-
More Information
Article History
Received: 19 May 2025
Accepted: 26 August 2025
First Online: 29 September 2025
Declarations
:
: LB declares to have acted as SAB member of Sanofi, Ionnis and NovoNordisk; to have received speaker fees from Sanofi and NovoNordisk and to have founded the Spin-off Ivastatin Therapeutics S (all unrelated to this work).T.P. discloses to have received speaker fees from AB-BIOTICS S.A. and to be a co-founder of Spin-off Ivastatin Therapeutics S.L. (both unrelated to this study).G.V. discloses to be a co-founder of Spin-off Ivastatin Therapeutics S.L. (unrelated to this study).The remaining authors have no competing interests to declare.
